Recently, the first commercial applications of MicroPort EP's Magbot™ Robotic Magnetic Navigation-driven product series in Europe were successfully completed in Finland and Germany, marking the official entry of the Magbot™ series into the commercial application stage in the European market and further demonstrating the competitiveness and influence of Chinese innovative electrophysiology technology in the global advanced procedural landscape.

The products in this series — the FireMagic™ Magbot™ Ablation Catheter (hereinafter referred to as the "FireMagic™ Magbot™ catheter") and the EasyStars™ Magbot™ High Density Mapping Catheter (hereinafter referred to as the "EasyStars™ Magbot™ catheter") — received EU MDR certification in February of this year.

At Meilahti Tower Hospital in Finland, Professor Pekka and his team successfully performed five arrhythmia procedures using the FireMagic™ Magbot™ catheter and the EasyStars™ Magbot™ catheter, including three cases of atrial fibrillation (AF), one atrioventricular node ablation (AVN Ablation), and one case of atrioventricular nodal reentrant tachycardia (AVNRT).

Notably, the EasyStars™ Magbot™ catheter achieved its first human clinical application during these procedures. Combined with the automated mapping technology of the Columbus™ 3D Cardiac Electrophysiological Mapping System, it significantly improved the efficiency of 3D modeling and voltage mapping, providing reliable support for high-quality ablation. This achievement fills a technological gap in the clinical application of magnetic navigation systems for high-density mapping and lays the foundation for subsequent large-scale clinical adoption.

During the procedure, the team first used the star-shaped mapping catheter to complete 3D modeling and automated voltage mapping, successfully accessing all four pulmonary veins. They then switched to the FireMagic™ Magbot™ catheter to perform pulmonary vein isolation (PVI) ablation directly on the existing model. Post-procedural results showed that the modeling results from the star-shaped mapping catheter were highly consistent with those from conventional ablation catheters.

Professor Pekka's team reported that the EasyStars™ Magbot™ catheter demonstrated excellent performance in modeling accuracy, signal stability, and operational efficiency, with particularly significant advantages in enhancing mapping efficiency. They gave high recognition to its clinical performance.

At Marienhaus Klinikum Neuwied-Waldbreitbach Hospital in Germany, Dr. Burkhard Hügl and his team successfully performed seven arrhythmia procedures using the FireMagic™ Magbot™ catheter, covering both first-time AF and AF recurrence patients.

After the procedures, the physician team gave high praise to the catheter's overall performance, particularly acknowledging its ablation efficiency, deflection capability, tissue contact stability, and signal clarity. The flexible tip of the FireMagic™ Magbot™ catheter maintains stable contact throughout the entire cardiac cycle while easily reaching complex anatomical regions that are difficult to access in conventional procedures.

The physicians noted that the magnetic-driven navigation system, through its flexible catheter design and precise control, reduces tissue damage and operational deviations, further optimizing procedural outcomes and potentially improving long-term treatment success rates.

The FireMagic™Magbot™ catheter integrates magnetic-driven navigation technology with 3D radiofrequency ablation technology, providing clinicians with an efficient, safe, and precise treatment option. The catheter incorporates embedded sensors and multiple magnetic blocks and is compatible with the Genesis RMN™ Robotic Magnetic Navigation System for Cardiac Electrophysiology.

Using the low-intensity magnetic field generated by the Genesis RMN™ system, physicians can precisely manipulate the FireMagic™ Magbot™ catheter within the patient's body, enabling the catheter to flexibly reach any position in the cardiac chamber and achieve precise navigation and stable control of the catheter tip, thereby further enhancing the precision and safety of complex arrhythmia treatments.

The successful completion of these first commercial applications in Europe not only validates the clinical value and technological maturity of the Magbot™ product series but also marks a new phase in MicroPort™ EP's globalization strategy. Moving forward, the company will continue to drive the global clinical adoption of innovative technologies, bringing more precise and efficient electrophysiology solutions to physicians and patients worldwide.